Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. 20% of patients treated with eblasakimab achieved EASI-100 (100% reduction in their ...

In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline, unblinded data from the full dataset expected at the end of 2024.Phase 2 proof-of-concept trial of farudodstat in alopecia areata (the FAST-A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Exhibit 99.1 PRESS RELEASE | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is ASLAN Pharmaceuticals Ltd. (ASLN) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.ASLAN Pharmaceuticals Ltd. is one of 1051 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms ...

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing twenty-five (25) ordinary shares, at an offering price of $1.00 per ADS in ...

ASLAN Pharmaceuticals Ltd. (ASLN) skyrocketed 160.8% on Mar 11 due to encouraging preliminary data reaffirming the potential of its investigational candidate, eblasakimab, to effectively treat atopic dermatitis (AD, also called eczema) patients. The intended patient population includes those previously treated with Sanofi (SNY) and Regeneron’s (REGN) blockbuster drug Dupixent (dupilumab).Eblasakimab, a novel monoclonal antibody, is an inhibitor of the IL-13 receptor sub-unit of the Type 2 receptor, which is ...

New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (G ...

https://reportify-1252068037.cos.apbeijing.myqcloud.com/media/production/ASLN7 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023 - Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024 - Expected ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------| | Securities registered or to be registered, pursuant to Section 12(b) of the Act: \nTitle of each class | Trading Symbol | Name of each exchange on which registered | | American Depositary Shares ( ...